Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration‐QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers

Bruton's tyrosine kinase (BTK) is a key regulator of B cell receptor and Fc receptor signaling, and a rational therapeutic target for autoimmune diseases. This first‐in‐human phase I, double‐blind, placebo‐controlled trial investigated the safety, tolerability, pharmacokinetics (PK), target occ...

Descripción completa

Detalles Bibliográficos
Autores principales: Becker, Andreas, Martin, Emily C., Mitchell, David Y., Grenningloh, Roland, Bender, Andrew T., Laurent, Julien, Mackenzie, Harald, Johne, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7070898/
https://www.ncbi.nlm.nih.gov/pubmed/31654487
http://dx.doi.org/10.1111/cts.12713

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7070898/
https://www.ncbi.nlm.nih.gov/pubmed/31654487
http://dx.doi.org/10.1111/cts.12713

Ejemplares similares